Latest Tax Incentives News

Godolphin Resources has unveiled a significant polymetallic sulphide discovery at Cousin Jack within its Lewis Ponds Project, alongside progressing an IPO to spin out its Narraburra Rare Earths asset into Matrix Critical Minerals.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.

Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.

Clever Culture Systems has doubled its large pharmaceutical customer base to eight, installed 34 APAS Independence instruments, and expects FY27 sales growth driven by existing and new customers. The company maintains a $1.7 million cash balance, raised $1.6 million in short-term debt, and is expanding validation services.

Right Resources’ latest quarter reveals a promising new Reduced Intrusion-Related Gold System and high-grade tungsten discoveries at Tumbarumba, backed by a $2.7 million capital raise.

Miramar Resources has doubled its gold Exploration Target at the Gidji JV near Kalgoorlie and completed its first drilling program at Chain Pool in over 60 years, while finalising the sale of Randalls Project and securing government grants to fund ongoing exploration.

Parkway Corporate delivered a record $7.25 million quarterly revenue and $0.54 million EBITDA, powered by a major water infrastructure contract. The company progressed key approvals for its Queensland Brine Management Complex and struck a strategic collaboration with Hitachi to develop advanced brine concentration technology.

PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

Centaurus Metals has made significant strides towards a Final Investment Decision for its Jaguar Nickel Sulphide Project, securing strong debt financing interest, critical infrastructure approvals, and advancing engineering and pre-development works in Brazil.

Sea Forest Limited accelerated its commercial momentum in 4Q26 with an 83% revenue increase to $2.1 million, underpinned by new cattle supply agreements and the commissioning of its first regional distribution centre in Newcastle.

Carnegie Clean Energy has made substantial progress on its ACHIEVE Programme, including module assembly and regulatory approvals for ocean deployment in Spain, supported by a $2.5 million private placement to fund commercial expansion.